贝伐珠单抗联合边界带立体定向放射外科治疗复发或进展性多形性胶质母细胞瘤的II期研究
这项II期研究评估贝伐珠单抗联合边界带立体定向放射外科(BZ-SRS)治疗复发胶质母细胞瘤的总生存期。2015至2017年计划入组40例,实际入组16例,中位总生存期11.73个月,与机构历史对照8.74个月相比无显著差异(P=0.324)。BZ-SRS联合贝伐珠单抗可行且耐受良好,但未显示显著生存获益。
要点
- BZ-SRS联合贝伐珠单抗治疗复发胶质母细胞瘤可行且耐受良好,未报告放射性坏死。
- 中位总生存期BZ-SRS组11.73个月 vs 历史对照组8.74个月,P=0.324,无显著差异。
- 6个月无进展生存率31.2%(p=0.00294),6个月总生存率81.2%(p=0.058)。
核心结论
- BZ-SRS联合贝伐珠单抗可行且耐受良好;与机构历史对照相比无显著生存获益;二次分析显示6个月无进展生存有改善趋势,但6个月总生存无改善趋势;MRS扫描未导致SRS治疗计划改变。
研究设计与样本
- II期研究,纳入组织学确诊的复发胶质母细胞瘤患者,既往接受过一线分次放疗和化疗且适合SRS。
- 计划入组40例,2015至2017年实际入组16例,中位年龄62岁(范围48-74岁)。
- 贝伐珠单抗10 mg/kg于第-1天、第14天给药,之后每14天一次直至疾病进展。
- BZ-SRS术前1-14天行脑MRI/MRS,以胆碱/NAA指数(CNI)面积≥3为SRS靶区。
主要发现
- 3/16(0.188)例参与者发生2级毒性,未报告放射性坏死(AREs)。
- 中位总生存期BZ-SRS组11.73个月 vs 机构历史对照组8.74个月(P=0.324)。
- 6个月无进展生存率31.2%(p=0.00294),6个月总生存率81.2%(p=0.058)。
- 13例可评估最佳疗效:完全缓解1例(p=0.077)、部分缓解4例(p=0.308)、疾病稳定7例(p=0.538)、疾病进展1例(p=0.077)。
- 11/16例参与者行MRS扫描,MRS改变治疗计划的估计概率为0(0,0.285)。
关键数值与推荐
- MRS以胆碱/NAA指数(CNI)面积≥3作为SRS靶区标准。
- 贝伐珠单抗剂量10 mg/kg,第-1天、第14天给药,之后每14天一次直至疾病进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 计划入组40例,实际仅入组16例。
- 与机构历史对照比较,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent glioblastoma is universally fatal with limited effective treatment options. The aim of this phase 2 study of Border Zone SRS plus bevacizumab was to evaluate OS in patients with recurrent GBM. METHODS: Patients with histologically confirmed GBM with recurrent disease who had received prior first-line treatment with fractionated radiotherapy and chemotherapy and eligible for SRS were enrolled. Bevacizumab 10 mg/kg was given day -1, day 14, and then every 14 days until disease progression. 1-14 days before BZ-SRS procedure, patients underwent brain MRI /MRS. MRS with measurement of choline-to-N-acetyl aspartate index (CNI) area ≥ 3 was targeted for SRS. RESULTS: From 2015-2017, sixteen of planned 40 patients were enrolled. The median age was 62 (range, 48-74Y). 3/16 (0.188) participants experienced grade 2 toxicity. No AREs were reported. The mOS was 11.73 months compared to 8.74 months (P = 0.324) from date of SRS for the BZ-SRS and institutional historical controls, respectively. PFS-6 and OS-6 were 31.2% (p = 0.00294) and 81.2%(p = 0.058), respectively. Of 13 evaluable for best response: 1 CR (p = 0.077), 4 PR (p = 0.308), 7 SD (p = 0.538), and 1 PD (p = 0.077). 11/16 participants had MRS scans with an estimated probability that MRS changes a treatment plan of 0 (0, 0.285). CONCLUSION: BZ-SRS with bevacizumab was feasible and well tolerated. There is no significant survival benefit using BZ-SRS with bevacizumab compared to institutional historical controls. Secondary analysis revealed a trend toward improved PFS-6, but not OS-6 after BZ-SRS. MRS scans did not result in changes to SRS treatment plans.
引用
- Mantica M, Drappatz J, Lieberman F, et al. Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme. J Neurooncol. 2023. PMID: 37515669. doi:10.1007/s11060-023-04398-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。